title: Erythropoietin treatment decreases cardiovascular morbidity and mortality in CAPD patients.
abstract: OBJECTIVE
  To analyze the effects of recombinant human erythropoietin (rHuEPO) therapy on cardiovascular (CV) morbidity and mortality among continuous ambulatory peritoneal dialysis (CAPD) patients.
  
  
  METHODS
  Retrospective comparative study.
  
  
  METHODS
  CAPD unit in a university hospital.
  
  
  METHODS
  Forty-two patients on rHuEPO treatment for at least one year were compared with an rHuEPO nonuser group of 113 patients. Subcutaneous rHuEPO doses were adjusted to a hemoglobin objective level of 10.5-13.5 g/dL. Fifty-seven patients were considered as high cardiovascular risk (HCVR), 17 in the rHuEPO group and 40 in the rHuEPO nonuser group. Ninety-eight patients were classified as low cardiovascular risk (LCVR), 25 of whom were in the rHuEPO group.
  
  
  RESULTS
  The incidence of cardiovascular morbidity was more frequent in the rHuEPO nonuser than in the rHuEPO user group (40% vs 22%) and in HCVR than in LCVR patients (59.6% vs 20.4%). By multiple logistic regression analysis, the best model to explain the development of cardiovascular morbidity comprises rHuEPO treatment, CV risk, and age. In the rHuEPO user group, HCVR and LCVR patients did not show significant differences in survival, while in the rHuEPO nonuser group, HCVR patients had a lower survival rate than LCVR patients (p = 0.0003). Cox proportional hazards model revealed that LCVR patients had an excellent prognosis compared with HCVR patients in the rHuEPO nonuser group, but this difference disappeared in the rHuEPO user group.
  
  
  CONCLUSIONS
  These data show a beneficial effect of rHuEPO treatment on cardiovascular morbidity and mortality in CAPD patients, evidenced by the elimination of the correlation between prior cardiovascular risk and subsequent mortality.
authors.affiliation: Hospital Universitario La Paz, Madrid, Spain.
authors.forename: M A
authors.initials: MA
authors.lastname: Bajo
authors.forename: R
authors.initials: R
authors.lastname: Selgas
authors.forename: M J
authors.initials: MJ
authors.lastname: Castro
authors.forename: C
authors.initials: C
authors.lastname: Jiménez
authors.forename: M J
authors.initials: MJ
authors.lastname: Fernández-Reyes
authors.forename: G
authors.initials: G
authors.lastname: Del Peso
authors.forename: F
authors.initials: F
authors.lastname: De Alvaro
authors.forename: A L
authors.initials: AL
authors.lastname: Sanchez-Sicilia
mesh_terms: D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D011994:Recombinant Proteins; D012044:Regression Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin